BofA is Bullish on CRISPR Therapeutics AG (CRSP)

 CRISPR Therapeutics AG (NASDAQ:CRSP) is among the Growth Stock Portfolio: 12 Stock Picks By Cathie Wood.

On January 22, 2026, TheFly disclosed that Alec Stranahan, a BofA analyst. It reduced the price objective for CRISPR Therapeutics AG (NASDAQ:CRSP) from $90 to $89 and retained a buy rating. Casgevy’s 2026 projections were slightly lowered as a result of the modification. Based on an earnings preview paper covering the biotechnology group, BofA still projects consecutive improvement for Casgevy through 2026 despite the change.

CRISPR Therapeutics AG (NASDAQ:CRSP) separately announced its planned 2026 milestones and strategic priorities on January 12, 2026. As per the company, Casgevy is gaining traction, and quarterly updates and ongoing worldwide commercialization are anticipated. It is projected that Casgevy regulatory submissions for patients aged 5 to 11 will start in the first half of 2026. According to the firm, additional significant events include the Lp(a) program in 2026 and advancements from CTX310. Furthermore, it includes autoimmune and immuno-oncology updates for zugocabtagene geleucel, as well as top-line Phase 2 data from CTX611 in the second half of 2026. Additionally, the advancements include the planned start of clinical trials for CTX460 in the middle of 2026 and CTX340 in the first half of 2026.

CRISPR Therapeutics AG (NASDAQ:CRSP) is a gene editing firm.

While we acknowledge the potential of CRSP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 20 Best Performing Stocks in 2025 and 12 Best Food Stocks to Buy in 2026. 

Disclosure: None. This article is originally published at Insider Monkey.